Reelin treatment rescue via ApoER2 in CD2AP mutant mice

Validation Score: 0.870 Price: $0.50 Alzheimer's disease mice Status: proposed

What This Experiment Tests

Validation experiment designed to validate causal mechanisms targeting CD2AP in mice. Primary outcome: increased resting cerebral blood flow and protection against Aβ toxicity

Description

Therapeutic intervention using reelin glycoprotein to mitigate CD2AP loss-of-function effects through ApoER2 receptor signaling. This experiment tested whether reelin treatment could rescue cerebrovascular dysfunction in CD2AP mutant mice by activating compensatory pathways. The study measured resting cerebral blood flow improvements and protection against amyloid-beta toxicity, with particular focus on male mice showing enhanced therapeutic response.

TARGET GENE

CD2AP

MODEL SYSTEM

mice

ESTIMATED COST

TIMELINE

0 months

PATHWAY

reelin-ApoER2 signaling, cerebrovascular function

SOURCE

extracted_from_pmid_39892386

PRIMARY OUTCOME

increased resting cerebral blood flow and protection against Aβ toxicity

Scoring Dimensions

📖 Wiki Pages

Protocol

Establish mice cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for CD2AP, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure increased resting cerebral blood flow and protection against Aβ toxicity together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5.

...

Expected Outcomes

The intervention targeting CD2AP shifts increased resting cerebral blood flow and protection against Aβ toxicity in the predicted direction relative to the matched control arm.

Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.

The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.

Success Criteria

Prespecified primary endpoint (increased resting cerebral blood flow and protection against Aβ toxicity) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.

Related Hypotheses (5)

TREM2-mediated microglial tau clearance enhancement0.618

LRP1-Dependent Tau Uptake Disruption0.600

VCP-Mediated Autophagy Enhancement0.595

Extracellular Vesicle Biogenesis Modulation0.582

HSP90-Tau Disaggregation Complex Enhancement0.575

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.